Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-614-5220
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees228
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Aimmune Therapeutics (NASDAQ:AIMT) Frequently Asked Questions
What is Aimmune Therapeutics' stock symbol?
Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT."
How were Aimmune Therapeutics' earnings last quarter?
Aimmune Therapeutics Inc (NASDAQ:AIMT) issued its earnings results on Thursday, August, 8th. The biotechnology company reported ($1.01) EPS for the quarter, missing the Zacks' consensus estimate of ($0.93) by $0.08. During the same quarter last year, the firm earned ($0.91) EPS. View Aimmune Therapeutics' Earnings History.
When is Aimmune Therapeutics' next earnings date?
What price target have analysts set for AIMT?
7 brokers have issued 1-year target prices for Aimmune Therapeutics' stock. Their forecasts range from $30.00 to $79.00. On average, they expect Aimmune Therapeutics' share price to reach $45.00 in the next twelve months. This suggests a possible upside of 93.2% from the stock's current price. View Analyst Price Targets for Aimmune Therapeutics.
What is the consensus analysts' recommendation for Aimmune Therapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aimmune Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aimmune Therapeutics.
What are Wall Street analysts saying about Aimmune Therapeutics stock?
Here are some recent quotes from research analysts about Aimmune Therapeutics stock:
- 1. Stifel Nicolaus analysts commented, "We continue to expect the focus of the Adcom to be on safety – risk of anaphylaxis and use of epinephrine – which is not new" news and we think also around the long-term use/safety of AR101 in patients (i.e. EoE). We think this should provide some relief for shares today as the investors’ worst case" scenario in terms of the panel may be off the table as the agency struck a relatively positive tone in the docs, in our view. With the stock continuing to move up ahead of the Adcom, we think the risk/reward at these levels is less favorable once Palforzia is approved given the commercial/logistical challenges we feel lay ahead, which is core to our thesis, and the Adcom isn’t completely devoid of risk." (9/11/2019)
- 2. According to Zacks Investment Research, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. " (9/5/2019)
Has Aimmune Therapeutics been receiving favorable news coverage?
Media stories about AIMT stock have been trending somewhat positive this week, InfoTrie reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aimmune Therapeutics earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Aimmune Therapeutics.
Are investors shorting Aimmune Therapeutics?
Aimmune Therapeutics saw a increase in short interest in August. As of August 31st, there was short interest totalling 12,061,000 shares, an increase of 12.2% from the July 31st total of 10,746,000 shares. Based on an average daily volume of 554,000 shares, the short-interest ratio is presently 21.8 days. Currently, 31.2% of the shares of the stock are sold short. View Aimmune Therapeutics' Current Options Chain.
Who are some of Aimmune Therapeutics' key competitors?
Some companies that are related to Aimmune Therapeutics include Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC), The Medicines (MDCO), Allakos (ALLK), FibroGen (FGEN), Alkermes (ALKS), Nektar Therapeutics (NKTR), United Therapeutics (UTHR), Evotec (EVTCY), Mirati Therapeutics (MRTX) and Global Blood Therapeutics (GBT).
What other stocks do shareholders of Aimmune Therapeutics own?
Who are Aimmune Therapeutics' key executives?
Aimmune Therapeutics' management team includes the folowing people:
- Dr. Jayson Donald Alexander Dallas, Pres, CEO & Director (Age 51)
- Mr. Eric H. Bjerkholt, Chief Financial Officer (Age 59)
- Mr. Douglas T. Sheehy, Gen. Counsel & Sec. (Age 52)
- Dr. Stephen George Dilly, Special Advisor (Age 59)
- Dr. Daniel C. Adelman, Chief Medical Officer (Age 62)
When did Aimmune Therapeutics IPO?
(AIMT) raised $124 million in an IPO on Thursday, August 6th 2015. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray acted as the underwriters for the IPO.
Who are Aimmune Therapeutics' major shareholders?
Aimmune Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (8.37%), Vanguard Group Inc. (5.91%), BlackRock Inc. (5.65%), Victory Capital Management Inc. (1.79%), Eagle Asset Management Inc. (1.66%) and Emerald Advisers LLC (1.35%). Company insiders that own Aimmune Therapeutics stock include Bakker Juliet Tammenoms, Daniel C Md Adelman, Douglas T Sheehy, Eric Bjerkholt, Jayson Donald Alexander Dallas, Kathryn E Falberg, Mary M Rozenman, Patrick G Enright, Stephen George Dilly and Susan E Barrowcliffe. View Institutional Ownership Trends for Aimmune Therapeutics.
Which institutional investors are selling Aimmune Therapeutics stock?
AIMT stock was sold by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., BlackRock Inc., RMB Capital Management LLC, Bank of America Corp DE, Emerald Advisers LLC, Wells Fargo & Company MN, Fiera Capital Corp and BNP Paribas Arbitrage SA. View Insider Buying and Selling for Aimmune Therapeutics.
Which institutional investors are buying Aimmune Therapeutics stock?
AIMT stock was bought by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Point72 Asset Management L.P., Sanders Morris Harris LLC, Nuveen Asset Management LLC, Vanguard Group Inc., Rice Hall James & Associates LLC, Bank of New York Mellon Corp and Balyasny Asset Management LLC. Company insiders that have bought Aimmune Therapeutics stock in the last two years include Bakker Juliet Tammenoms, Eric Bjerkholt, Jayson Donald Alexander Dallas, Kathryn E Falberg and Patrick G Enright. View Insider Buying and Selling for Aimmune Therapeutics.
How do I buy shares of Aimmune Therapeutics?
Shares of AIMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Aimmune Therapeutics' stock price today?
One share of AIMT stock can currently be purchased for approximately $23.29.
How big of a company is Aimmune Therapeutics?
Aimmune Therapeutics has a market capitalization of $1.46 billion. The biotechnology company earns $-210,750,000.00 in net income (profit) each year or ($3.67) on an earnings per share basis. Aimmune Therapeutics employs 228 workers across the globe.View Additional Information About Aimmune Therapeutics.
What is Aimmune Therapeutics' official website?
How can I contact Aimmune Therapeutics?
Aimmune Therapeutics' mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-614-5220 or via email at [email protected]
MarketBeat Community Rating for Aimmune Therapeutics (NASDAQ AIMT)
MarketBeat's community ratings are surveys of what our community members think about Aimmune Therapeutics and other stocks. Vote "Outperform" if you believe AIMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AIMT will underperform the S&P 500 over the long term. You may vote once every thirty days.
